vascular endothelial growth factor

Early detection in AMD: An ounce of prevention is worth a pound of cureInterventions in AMD are most effective when administered early in the disease course. Studies provide evidence supporting this and a number of tools and techniques can be used to improve rates of early detection to improve patients’ long-term outcomes.
Cataract surgery may raise diabetic macular oedema riskCataract surgery increases the risk of diabetic macular oedema (DMO), medical records from the United Kingdom suggest. An analysis of 4,850 eyes showed that the rate of DMO requiring treatment spiked about 4 months after the surgery.
Data demonstrate real-world benefits of fluocinolone acetonide implantReal-world data on a fluocinolone acetonide intravitreal implant show sustained benefits of switching to the treatment in pseudophakic eyes that are insufficiently responsive to other therapies.
Investigational drug Luminate targets integrin receptorsAnti-integrin therapy is a promising new approach in the treatment of vitreoretinal disease. The first drug in this class, Allegro Ophthalmics’ Luminate, is in Phase 2 clinical trials for several indications, including wet age-related macular degeneration, diabetic macular edema, non-proliferative diabetic retinopathy, and vitreomacular traction.
Topical drug delivery via mucus-penetrating particles blocks VEGF signalingA topical receptor tyrosine kinase inhibitor may be a potential noninvasive inhibitor of vascular endothelial growth factor signaling.